- Bay Area Times
- Posts
- Trump vetoed Israeli plan to kill Iran’s supreme leader, as war continues, oil, stocks little changed
Trump vetoed Israeli plan to kill Iran’s supreme leader, as war continues, oil, stocks little changed
Bay Area Times
June 16, 2025
Brought to you by:
Top stories today:
- Trump vetoed Israeli plan to kill Iran’s supreme leader, as war continues
- Longevity investment 2x’d YoY to $8.5B in 2024
- Ramp said to have raised $200M at $16B valuation in new round
- Anne Wojcicki set to regain control of 23andMe after winning bid
- Global influencer marketing projected at +36% in 2025 to $33B
0. Data and calendar
All values as of 6 AM ET / 3 AM PT, other than S&P500 and NASDAQ close (4 PM ET / 1 PM PT).
All times are ET.
Listen to our AI-generated podcast summarizing today’s newsletter (beware of hallucinations):
1. Trump vetoed Israeli plan to kill Iran’s supreme leader, as war continues, oil, stocks little changed
Israel and Iran may need to “fight it out” before a deal, Trump also said.
“Open” to Putin’s idea to serve as a mediator, Trump stated.
“[W]e’ll do what we need to do,” the Israeli PM said.
The tensions between Israel and Iran have been escalating since Oct. 2023
Virtuix’s Omni One is a full-body VR treadmill that turns Fortnite into a fitness experience, allowing you to walk, run, crouch, jump, and sweat inside your favorite game.
400,000+ users. $18M in sales. Now, even the U.S. Air Force wants in on battle training.
Backed by Mark Cuban. Public investing on StartEngine, starting at just $500.
*Disclaimer: This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
3. Longevity investment 2x’d YoY to $8.5B in 2024
325 deals closed last year, vs. 331 deals in 2023.
$3.74B in Q1, making it the top quarter.
Late-stage funding was 31% of the total.
U.S.: 57% of companies, 84% of funding.
Imagine finding out too late… that the device that could’ve saved your dad’s life was already out there and you missed it:
Future Cardia built a tiny, under-the-skin heart monitor that tracks for heart failure and arrhythmias, 24/7.
Backed by Johnson & Johnson’s JLABS, 10,000+ investors, and already implanted in real patients with 60,000+ hours of data.
Targeting a $65B market dominated by Medtronic & Abbott. You can invest starting at just $348.
*Disclaimer: *This product is not yet available for purchase and requires review and clearance before being marketed or sold. This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
5. Ramp said to have raised $200M at $16B valuation in new round led by Founders Fund
